AME Cloud Ventures

Tracked participation in 2 Atlas companies, with 0 explicitly attributed leads.

2portfolio companies

7round participations

0lead positions

Jul 2019latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)Recursion—Oct 2016 → Jul 20194 roundsParticipant—

MMythic—Mar 2017 → Jun 20193 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Jul 15, 2019RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries C$121M—Participant

Source ↗

Jun 12, 2019MMythicSeries B-1$30M—Participant

Source ↗

Mar 20, 2018MMythicSeries B$40M—Participant

Source ↗

Oct 03, 2017RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries B$60M—Participant

Source ↗

Mar 22, 2017MMythicSeries A$9M—Participant

Source ↗

Nov 22, 2016RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries A (additional close)$2.2M—Participant

Source ↗

Oct 03, 2016RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries A$12.9M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗

Mar 20, 2018MMythicSeries B$40M—Participant

Source ↗

Jun 12, 2019MMythicSeries B-1$30M—Participant

Source ↗

Mar 22, 2017MMythicSeries A$9M—Participant

Source ↗